News

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...
Johnson & Johnson is leading the S&P 500 and the Dow Jones Industrial Average after the drugmaker slashed its estimate for the impact of tariffs in 2025 and raised its outlook. The company’s stock is ...
C.J. Gardner-Johnson said he "retracts" the comments he made about the Philadelphia Eagles after he was traded to the Houston ...
In the second quarter, J&J’s worldwide oncology sales shot up more than 20 per cent, offsetting declines in sales of its ...
The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...
Johnson shared yet another personal insight that nobody asked for: His jizz has substantially more microplastics in it than ...
The third-term Democrat from Dallas faces long odds in a state that has only elected Republicans to statewide office for ...
Stay updated on Johnson & Johnson's Q2 earnings as it faces tariff threats, MedTech challenges, and legal risks.